Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/923,619external-prioritypatent/US7163937B2/en
Application filed by Bristol-Myers Squibb CompanyfiledCriticalBristol-Myers Squibb Company
Publication of CY1114816T1publicationCriticalpatent/CY1114816T1/en
Η παρούσα αίτηση περιγράφει ρυθμιστές MCP-1 του τύπου (I): ή φαρμακευτικώς αποδεκτές μορφές αλάτων αυτών, χρήσιμα για τη θεραπευτική αγωγή ρευματοειδούς αρθρίτιδας, σκλήρυνσης κατά πλάκας, αθηροσκλήρωσης και άσθματος.This application describes MCP-1 modulators of formula (I): or pharmaceutically acceptable salts thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
CY20141100026T2003-08-212014-01-14
CIRCULATED PRODUCTS AS CHEMICAL CHINESE ACTIVITY REGULATORS
CY1114816T1
(en)
fostamatinib or a pharmaceutically acceptable salt of fostamatinib, or a hydrate, solvate or N-oxide of fostamatinib or the pharmaceutically acceptable salt of fostamatinib, in particular fostamatinib disodium, optionally in the form of a hydrate